Table 1.
Baseline characteristics of the study patients.
| Variable | All patients (n = 1383) |
|---|---|
| Gender (male %) | 719 (52.0%) |
| Age (years) | 65.6 ± 12.6 |
| Duration of diabetes (years) | 10 ± 3.5 (4.2–13.0) |
| SBP (mmHg) | 132 ± 16.0 |
| DBP (mmHg) | 76 ± 9.7 |
| HbA1c (%) | 8.0 ± 1.8 (n = 1194) |
| HbA1c < 7% | 6.39 ± 0.46 |
| 7% ⩽ HbA1c < 9%, | 7.91 ± 0.56 |
| HbA1c ⩾ 9% | 10.59 ± 1.43 |
| HbA1c_CV | 10.24 ± 5.32 |
| HbA1c_CV in low tertile | 5.15 ± 1.57% |
| HbA1c_CV in middle tertile | 9.23 ± 1.2% |
| HbA1c_CV in high tertile | 16.33 ± 4.31% |
| eGFR (ml/min/1.73 m2) | 63.0 ± 23.8 |
| eGFR decline (ml/min/1.732 m2) per year | −1.79 (−2.20, −1.38) |
| Number of OADs | 1.4 ± 0.8 |
| 0 | 186 (13.4%) |
| 1 | 534 (38.6%) |
| 2 | 534 (38.6%) |
| 3 | 123 (8.9%) |
| 4 | 6 (0.4%) |
| Insulin usage | 287 (20.8%) |
| HTN medication | 1004 (72.6%) |
| ACEi or ARB (%) | 796 (57.6%) |
| Hyperlipidemia medication | 513 (37.1%) |
Data are presented as n (%) or mean ± SD.
ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin-receptor blockers; CV, coefficient of variation; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HTN, hypertension; OAD, oral anti-diabetic drug; SBP, systolic blood pressure; SD, standard deviation.